Several papers authored by international experts have proposed recommendations on the management of BCR-ABL11 chronic myeloid leukemia (CML). Following these recommendations, survival of CML patients has become very close to normal. The next, ambitious, step is to bring as many patients as possible into a condition of treatment-free remission (TFR). The Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA; Italian Group for Hematologic Diseases of the Adult) CML Working Party (WP) has developed a project aimed at selecting the treatment policies that may increase the probability of TFR, taking into account 4 variables: the need for TFR, the tyrosine kinase inhibitors (TKIs), the characteristics of leukemia, and the patient. A Delphi-like method was used to reach a consensus among the representatives of 50 centers of the CML WP. A consensus was reached on the assessment of disease risk (EUTOS Long Term Survival [ELTS] score), on the definition of the most appropriate age boundaries for the choice of first-line treatment, on the choice of the TKI for first-line treatment, and on the definition of the responses that do not require a change of the TKI (BCR-ABL1 ≤10% at 3 months, ≤1% at 6 months, ≤0.1% at 12 months, ≤0.01% at 24 months), and of the responses that require a change of the TKI, when the goal is TFR (BCR-ABL1 >10% at 3 and 6 months, >1% at 12 months, and >0.1% at 24 months). These suggestions may help optimize the treatment strategy for TFR.
Managing chronic myeloid leukemia for treatment-free remission: A proposal from the GIMEMA CML WP / Baccarani M.; Abruzzese E.; Accurso V.; Albano F.; Annunziata M.; Barulli S.; Beltrami G.; Bergamaschi M.; Binotto G.; Bocchia M.; Caocci G.; Capodanno I.; Cavazzini F.; Cedrone M.; Cerrano M.; Crugnola M.; D'Adda M.; Elena C.; Fava C.; Fazi P.; Fozza C.; Galimberti S.; Giai V.; Gozzini A.; Gugliotta G.; Iurlo A.; la Barba G.; Levato L.; Lucchesi A.; Luciano L.; Lunghi F.; Lunghi M.; Malagola M.; Marasca R.; Martino B.; Melpignano A.; Miggiano M.C.; Montefusco E.; Musolino C.; Palmieri F.; Pregno P.; Rapezzi D.; Rege-Cambrin G.; Rupoli S.; Salvucci M.; Sancetta R.; Sica S.; Spadano R.; Stagno F.; Tiribelli M.; Tomassetti S.; Trabacchi E.; Bonifacio M.; Breccia M.; Castagnetti F.; Pane F.; Russo D.; Saglio G.; Soverini S.; Vigneri P.; Rosti G.. - In: BLOOD ADVANCES. - ISSN 2473-9529. - ELETTRONICO. - 3:24(2019), pp. 4280-4290. [10.1182/bloodadvances.2019000865]
Managing chronic myeloid leukemia for treatment-free remission: A proposal from the GIMEMA CML WP
Baccarani M.
;Gugliotta G.;Lucchesi A.;Malagola M.;Castagnetti F.;Soverini S.;Rosti G.
2019
Abstract
Several papers authored by international experts have proposed recommendations on the management of BCR-ABL11 chronic myeloid leukemia (CML). Following these recommendations, survival of CML patients has become very close to normal. The next, ambitious, step is to bring as many patients as possible into a condition of treatment-free remission (TFR). The Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA; Italian Group for Hematologic Diseases of the Adult) CML Working Party (WP) has developed a project aimed at selecting the treatment policies that may increase the probability of TFR, taking into account 4 variables: the need for TFR, the tyrosine kinase inhibitors (TKIs), the characteristics of leukemia, and the patient. A Delphi-like method was used to reach a consensus among the representatives of 50 centers of the CML WP. A consensus was reached on the assessment of disease risk (EUTOS Long Term Survival [ELTS] score), on the definition of the most appropriate age boundaries for the choice of first-line treatment, on the choice of the TKI for first-line treatment, and on the definition of the responses that do not require a change of the TKI (BCR-ABL1 ≤10% at 3 months, ≤1% at 6 months, ≤0.1% at 12 months, ≤0.01% at 24 months), and of the responses that require a change of the TKI, when the goal is TFR (BCR-ABL1 >10% at 3 and 6 months, >1% at 12 months, and >0.1% at 24 months). These suggestions may help optimize the treatment strategy for TFR.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
